Cite
Wojnarowicz PM, Escolano MG, Huang YH, et al. Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ Breast Cancer. 2021;7(1):58doi: 10.1038/s41523-021-00266-0.
Wojnarowicz, P. M., Escolano, M. G., Huang, Y. H., Desai, B., Chin, Y., Shah, R., Xu, S., Yadav, S., Yaklichkin, S., Ouerfelli, O., Soni, R. K., Philip, J., Montrose, D. C., Healey, J. H., Rajasekhar, V. K., Garland, W. A., Ratiu, J., Zhuang, Y., Norton, L., Rosen, N., Hendrickson, R. C., Zhou, X. K., Iavarone, A., Massague, J., Dannenberg, A. J., Lasorella, A., & Benezra, R. (2021). Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ breast cancer, 7(1), 58. https://doi.org/10.1038/s41523-021-00266-0
Wojnarowicz, Paulina M, et al. "Anti-tumor effects of an ID antagonist with no observed acquired resistance." NPJ breast cancer vol. 7,1 (2021): 58. doi: https://doi.org/10.1038/s41523-021-00266-0
Wojnarowicz PM, Escolano MG, Huang YH, Desai B, Chin Y, Shah R, Xu S, Yadav S, Yaklichkin S, Ouerfelli O, Soni RK, Philip J, Montrose DC, Healey JH, Rajasekhar VK, Garland WA, Ratiu J, Zhuang Y, Norton L, Rosen N, Hendrickson RC, Zhou XK, Iavarone A, Massague J, Dannenberg AJ, Lasorella A, Benezra R. Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ Breast Cancer. 2021 May 24;7(1):58. doi: 10.1038/s41523-021-00266-0. PMID: 34031428; PMCID: PMC8144414.
Copy
Download .nbib